Payment overview · 2025
General Payments
$649.13
30 reported records · 12 companies
Healthcare provider profile · identity verified
Cheryl A Canto, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT HURON, MI · NPI 1164423216
Verified facts
What the public records show
CMS Open Payments records show Cheryl A Canto, M.D. received $649.13 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.45 | 23.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $123.39 | 19.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.59 | 9.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.99 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.45 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.58 | 7.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.07 | 4.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.01 | 4.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.70 | 4.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.99 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.82 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.09 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $649.13 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $131.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $123.39 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $60.59 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.99 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.99 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $31.70 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 547 | 132 |
| Furosemide | Furosemide | 512 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 140 |
| Gabapentin | Gabapentin | 404 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 91 |
| Montelukast Sodium | Montelukast Sodium | 311 | 91 |
| Alprazolam | Alprazolam | 288 | 57 |
| Eliquis | Apixaban | 275 | 43 |
| Omeprazole | Omeprazole | 275 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 48 |
| Potassium Chloride | Potassium Chloride | 274 | 67 |
| Lisinopril | Lisinopril | 272 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 58 |
| Losartan Potassium | Losartan Potassium | 214 | 62 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 204 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 166 | 34 |
| Prednisone | Prednisone | 162 | 96 |
| Allopurinol | Allopurinol | 149 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 45 |
| Mounjaro | Tirzepatide | 145 | 25 |
| Jardiance | Empagliflozin | 139 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 47 |
| Trazodone Hcl | Trazodone Hcl | 137 | 47 |
| Celecoxib | Celecoxib | 134 | 35 |
| Tramadol Hcl | Tramadol Hcl | 133 | 37 |
| Bupropion Xl | Bupropion Hcl | 131 | 37 |
| Metformin Hcl | Metformin Hcl | 124 | 39 |
| Sertraline Hcl | Sertraline Hcl | 121 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 116 | 27 |
| Ozempic | Semaglutide | 114 | 17 |
| Simvastatin | Simvastatin | 111 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 34 |
| Buspirone Hcl | Buspirone Hcl | 105 | 27 |
| Pregabalin | Pregabalin | 105 | 19 |
| Ibuprofen | Ibuprofen | 103 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 28 |
| Valsartan | Valsartan | 101 | 30 |
| Clonazepam | Clonazepam | 99 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 35 |
| Xarelto | Rivaroxaban | 92 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 27 |
| Cefuroxime | Cefuroxime Axetil | 85 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 20 |
| Famotidine | Famotidine | 78 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 28 |
| Atenolol | Atenolol | 71 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 24 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 71 | suppressed |
| Methocarbamol | Methocarbamol | 68 | 33 |
| Azithromycin | Azithromycin | 65 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 24 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 16 |
| Baclofen | Baclofen | 62 | 15 |
| Ezetimibe | Ezetimibe | 62 | 20 |
| Glimepiride | Glimepiride | 62 | 21 |
| Irbesartan | Irbesartan | 62 | 16 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Spironolactone | Spironolactone | 61 | 20 |
| Memantine Hcl | Memantine Hcl | 60 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Lactulose | Lactulose | 56 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 12 |
| Enulose | Lactulose | 54 | suppressed |
| Carvedilol | Carvedilol | 53 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 51 | 36 |
| Risedronate Sodium | Risedronate Sodium | 50 | 18 |
| Alendronate Sodium | Alendronate Sodium | 49 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 36 |
| Labetalol Hcl | Labetalol Hcl | 47 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 46 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 44 | 15 |
| Novolog Flexpen | Insulin Aspart | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 13 |
| Metolazone | Metolazone | 40 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 15 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Lansoprazole | Lansoprazole | 38 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 11 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Repaglinide | Repaglinide | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Metronidazole | Metronidazole | 32 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Topiramate | Topiramate | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Diazepam | Diazepam | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 11 |
| Invokana | Canagliflozin | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Mupirocin | Mupirocin | 22 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 13 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Dexamethasone | Dexamethasone | 16 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $649.13 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error